Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2019-10-24 Interim / Quarterly Rep…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Q3 verslag 2019.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Derde kwartaalverslag 2019' (Third Quarter Report 2019) for Galapagos. It contains detailed financial statements, management discussion and analysis (MDA), operational highlights, and audit information for the nine-month period ending September 30, 2019. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2019
2019-10-24 Dutch
6-K Filing
Regulatory Filings
2019-10-23 English
GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS
Earnings Release Classification · 95% confidence The document is a press release, dated October 11, 2019, jointly issued by Gilead Sciences and Galapagos NV. It announces the 52-week results from their Phase 3 FINCH 1 and 3 studies for the drug filgotinib for rheumatoid arthritis. The text details clinical outcomes, mentions future presentations at medical conferences, and discusses upcoming regulatory submissions (EMA evaluation, Japanese submission, and future US NDA filing). This content—announcing clinical trial results and providing updates on regulatory progress—is characteristic of an Earnings Release (ER) or a general press announcement related to business operations and pipeline progress. Since it is a specific announcement of results rather than a comprehensive periodic report (like 10-K or IR), and it is not a transcript (CT) or a formal presentation (IP), the most fitting category is Earnings Release (ER), as these often include key clinical/operational updates alongside financial highlights (though financials are minimal here, the structure is that of a results announcement). It is not a Report Publication Announcement (RPA) because it contains the substantive results, not just a notice that a report is available. Q4 2019
2019-10-11 Dutch
GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS
Legal Proceedings Report Classification · 99% confidence The document is a press release dated October 11, 2019, announcing the Week 52 efficacy and safety results of the drug filgotinib from the FINCH 1 and FINCH 3 Phase 3 trials for Rheumatoid Arthritis. It quotes executives, summarizes key findings, and mentions regulatory submissions (EMA MAA, Japanese NDA) and future US NDA plans. This content structure—a formal announcement of clinical trial results and regulatory progress, often issued before a full report or presentation—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a transcript (CT), a full annual report (10-K), or a specific financial supplement (XLSX), and it focuses on clinical/pipeline updates rather than pure financial performance highlights, it fits best as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it's a specific clinical update not covered elsewhere. However, press releases announcing significant clinical trial data updates, especially those tied to regulatory milestones, are often categorized as Earnings Releases (ER) if they are periodic updates, or sometimes as Regulatory Filings (RNS). Given the focus on announcing key results that impact the company's outlook and the mention of regulatory filings, ER is a strong candidate, but RNS is the general fallback for significant, non-standard announcements. Since this is a major clinical data readout, which often accompanies or precedes quarterly reporting cycles, ER is plausible. However, looking closely at the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical data announcement, not a financial results announcement. Therefore, the most appropriate category for a significant, non-standard press release detailing clinical trial outcomes and regulatory progress is the general Regulatory Filings category (RNS).
2019-10-11 English
6-K Filing
Regulatory Filings
2019-10-11 English
GILEAD EN GALAPAGOS KONDIGEN VEILIGHEIDS-EN WERKZAAMHEIDSRESULTATEN AAN OVER FILGOTINIB NA 52 WEKEN IN FINCH 1 EN 3 STUDIES IN REUMA
Earnings Release Classification · 95% confidence The document is a press release issued by Gilead Sciences and Galapagos NV announcing the results of Phase 3 clinical trials (FINCH 1 and 3) for their drug candidate, filgotinib. It provides key highlights of the study outcomes, safety profiles, and regulatory status. While it discusses clinical data, it is an initial announcement of these results rather than a full scientific audit report or a quarterly financial report. It fits the definition of an Earnings Release or a general corporate press release regarding operational/clinical updates, which falls under the 'Earnings Release' (ER) category in this taxonomy as it serves as the primary announcement of material company news. Q2 2019
2019-10-11 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.